STOCK TITAN

Nexalin Technology (NXL) Financials

NXL NASDAQ
Trailing 12 months to June 30, 2026
Revenue $217K +24.2% YoY
Net Income -$9.0M n/m YoY
EPS (Diluted) -$0.48 YoY not available
Operating Cash Flow -$6.1M n/m YoY
Market Cap $1.8M as of Oct 26, 2026
Price / Sales 8.3x on $217K revenue, trailing 12 months to June 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026
Price / Book 1.2x on $1.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NXL SEC filings page.

Nexalin Technology, Inc. (NXL) reported $217K in revenue over the twelve months to Jun 30, 2026, up 24.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NXL FY2025

The business is scaling reported sales, but development and overhead spending still overwhelm gross profit and cash generation.

Revenue rose 78.8% from FY2024 to FY2025, while gross margin improved by 1.3 percentage points. Even so, operating cash outflow widened from $3.94M to $4.96M, showing that top-line growth and better unit economics have not yet made the operation self-funding.

FY2025 gross profit was only $240K, while research and development consumed $1.08M. Selling, general and administrative expense added $4.40M, so the cost base—not production cost alone—is the main reason reported losses remain large.

The balance sheet is less debt-heavy than the income statement suggests: liabilities were $887K against equity of $3.75M. A 4.8x current ratio indicates reported short-term assets exceed near-term obligations, while reported cash, cash equivalents, and investments equaled nine months of the latest annual operating outflow.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

Nexalin Technology, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress
-31.86

Nexalin Technology, Inc. scores -31.86, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $92.9M against total assets of $4.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/8

Nexalin Technology, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

Nexalin Technology, Inc. reported a net loss of $8.2M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Nexalin Technology, Inc. reported an operating loss of $8.4M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$12K
YoY-82.8%
QoQ-18.7%

Nexalin Technology, Inc. generated $12K in revenue in Q2 2026. This represents a decrease of 82.8% from the same quarter a year earlier. Against the prior quarter it is down 18.7%.

EBITDA
-$2.2M
QoQn/m

Nexalin Technology, Inc.'s EBITDA was -$2.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$2.2M
YoYn/m
QoQn/m

Nexalin Technology, Inc. reported a net loss of $2.2M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.11
YoYn/m
QoQn/m

Nexalin Technology, Inc. earned -$0.11 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$1.0M
YoY+133.0%
QoQ-16.8%

Nexalin Technology, Inc. held $1.0M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding
22M
YoY+26.5%
QoQ+7.1%

Nexalin Technology, Inc. had 22M shares outstanding in Q2 2026. This represents an increase of 26.5% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin
73.2%
YoY+5.5pp
QoQ-14.7pp

Nexalin Technology, Inc.'s gross margin was 73.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.7 percentage points.

Return on Equity
-147.4%
YoY-120.9pp
QoQ-74.7pp

Nexalin Technology, Inc.'s quarterly ROE was -147.4% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 120.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 74.7 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$564K
YoY+150.0%
QoQ+63.0%

Nexalin Technology, Inc. invested $564K in research and development in Q2 2026. This represents an increase of 150.0% from the same quarter a year earlier. Against the prior quarter it is up 63.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

NXL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXL quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Revenue$12K-82.8%$15K-63.5%$172K+532.5%$18K-49.6%$71K+163.0%$41K-47.9%$27K+32.4%$36K+49.4%
Cost of Revenue$3K-85.7%$2K-86.6%$21K+180.5%$4K-68.9%$23K+215.1%$14K+48.1%$7K+43.3%$13K+219.5%
Gross Profit$9K-81.4%$13K-52.2%$151K+666.5%$14K-39.1%$48K+143.7%$27K-60.5%$20K+28.6%$23K+15.9%
R&D Expenses$564K+150.0%$346K-14.7%$225K-69.5%$227K+26.9%$226K+33.3%$406K+284.5%$737K+931.5%$179K-89.1%
SG&A Expenses$783K-12.4%$793K-14.7%$1.2M-14.4%$1.4M-21.0%$894K+49.3%$929K+92.3%$1.4Mn/m$1.8M-7.6%
Operating Income-$2.2Mn/m-$2.1Mn/m-$2.4Mn/m-$2.3Mn/m-$1.6Mn/m-$2.0Mn/m-$2.9Mn/m-$2.5Mn/m
EBITDA-$2.2M-$2.1MN/AN/AN/AN/AN/AN/A
Interest Expense-$129n/m-$34n/m-$159n/m-$2Kn/m-$5Kn/m-$1Kn/m-$2K-109.5%-$1K-118.8%
Net Income-$2.2Mn/m-$2.1Mn/m-$2.4Mn/m-$2.3Mn/m-$1.6Mn/m-$2.0Mn/m-$2.8Mn/m-$2.4Mn/m
EPS (Basic)-$0.11n/m-$0.11n/m-$0.13-$0.13-$0.10-$0.15-$0.28n/m-$0.23n/m
EPS (Diluted)-$0.11n/m-$0.11n/m-$0.13-$0.13-$0.10-$0.15-$0.28n/m-$0.23n/m
Diluted Shares (Avg)21M+34.5%20M+48.9%N/A18M16M13MN/A11M+46.3%

Not reported in any period shown, so not listed: Income Tax.

NXL Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXL quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$3.0M-54.2%$3.7M+27.4%$4.6M+9.8%$5.1M-2.5%$6.6M+319.9%$2.9M+2.3%$4.2M+16.3%$5.3M+18.6%
Current Assets$1.9M-70.3%$3.3M+25.6%$4.3M+8.5%$4.8M-1.8%$6.3M+430.3%$2.6M+2.2%$4.0M+15.5%$4.9M+15.1%
Cash & Equivalents$1.0M+133.0%$1.2M+94.2%$655K+14.0%$590K+624.7%$431K-49.2%$622K+13.9%$574K-1.0%$81K-77.5%
Short-Term Investments$0-100.0%$1.5M+5.0%$3.1M+5.6%$3.8M-16.6%$5.4Mn/m$1.4M-10.6%$2.9M+22.7%$4.5M+26.2%
Inventory$233K+35.0%$179K+2.4%$131K-24.7%$160K+1.2%$173K+19.2%$175K+14.0%$175K+11.6%$158K-0.2%
Accounts Receivable$53K-11.5%$43K+197.0%$82K+525.4%$8K-47.8%$60K+410.6%$14K+295.0%$13K+39.2%$15K+4.8%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$1.5M+147.2%$808K+40.6%$887K+62.3%$358K+19.4%$601K+183.2%$575K+13.3%$547K+28.5%$299K-75.0%
Current Liabilities$1.5M+147.2%$808K+40.6%$887K+62.3%$358K+19.4%$601K+183.2%$575K+13.3%$547K+28.5%$299K-75.0%
Non-Current Liabilities$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Equity$1.5M-74.5%$2.9M+24.1%$3.7M+2.0%$4.8M-3.8%$6.0M+341.4%$2.3M-0.1%$3.7M+14.6%$5.0M+53.2%
Retained Earnings-$97.2Mn/m-$95.0Mn/m-$92.9Mn/m-$90.5Mn/m-$88.2Mn/m-$86.6Mn/m-$84.6Mn/m-$81.8Mn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

NXL Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXL quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow-$1.8Mn/m-$1.7Mn/m-$1.1Mn/m-$1.5Mn/m-$917Kn/m-$1.4Mn/m-$1.1Mn/m-$800Kn/m
Depreciation & Amortization$3K$4KN/AN/AN/AN/AN/AN/A
Stock-Based CompensationN/A$479K-24.8%N/AN/AN/A$637K+294.7%N/AN/A
Investing Cash Flow$1.5Mn/m$1.5M+2.4%$689K-57.7%$1.6Mn/m-$3.9M-353.1%$1.5M+102.1%$1.6M+33.1%-$4.5M-639.7%
Financing Cash Flow$138K$756K$524Kn/m$0N/AN/A$0n/mN/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

NXL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NXL quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Gross Margin73.2%+5.5pp87.8%+20.9pp87.8%+15.4pp78.3%+13.5pp67.7%-5.3pp66.9%-21.4pp72.4%-2.1pp64.8%-18.8pp
Operating Margin-18479.7%-14179.9%-1403.9%-12924.3%-2296.2%-4903.6%-10579.5%-6962.1%
Net Margin-18412.7%-14025.7%-1382.6%-12542.3%-2239.7%-4847.8%-10424.5%-6794.9%
Return on Equity-147.4%-120.9pp-72.7%+12.9pp-63.4%+13.7pp-47.7%+1.6pp-26.5%+68.6pp-85.5%-40.8pp-77.1%-52.7pp-49.4%+21.6pp
Return on Assets-74.5%-50.4pp-56.8%+11.8pp-51.3%+15.8pp-44.4%+2.2pp-24.1%+58.1pp-68.6%-31.8pp-67.1%-45.6pp-46.6%+5.2pp
Current Ratio1.25-9.2x4.07-0.5x4.85-2.4x13.47-2.9x10.44+4.9x4.56-0.5x7.25-0.8x16.39+12.8x
Liabilities-to-Equity0.98+0.9x0.280.0x0.24+0.1x0.070.0x0.10-0.1x0.250.0x0.150.0x0.06-0.3x
Asset Turnover0.000.0x0.000.0x0.040.0x0.000.0x0.010.0x0.010.0x0.010.0x0.010.0x

Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Nexalin Technology, Inc. NXL FY2025 $302K -$8.2M N/A $1.8M —
Intelligent Bio Solutions Inc. INBS FY2026 $4.2M -$12.4M N/A $5.3M 48/100
enVVeno Medical Corporation NVNO FY2025 N/A -$19.5M N/A $4.6M —
Ainos, Inc. AIMD FY2025 $124K -$14.8M N/A $6.2M —
ALLURION TECHNOLOGIES ALUR FY2025 $15.2M -$28.8M N/A N/A —
Co-Diagnostics, Inc. CODX FY2025 $622K -$46.9M N/A $3.8M —

Frequently Asked Questions

What is Nexalin Technology, Inc.'s annual revenue?

Nexalin Technology, Inc. (NXL) reported $302K in total revenue for fiscal year 2025. This represents a 78.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nexalin Technology, Inc.'s revenue growing?

Nexalin Technology, Inc. (NXL) revenue grew by 78.8% year-over-year, from $169K to $302K in fiscal year 2025.

Is Nexalin Technology, Inc. profitable?

No, Nexalin Technology, Inc. (NXL) reported a net loss of $9.0M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $8.2M.

Nexalin Technology, Inc. (NXL) reported diluted earnings per share of -$0.50 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nexalin Technology, Inc. (NXL) had a gross margin of 79.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Nexalin Technology, Inc. (NXL) has a return on equity of -219.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Nexalin Technology, Inc. (NXL) recorded an outflow of $5.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Nexalin Technology, Inc. (NXL) had $4.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Nexalin Technology, Inc. (NXL) invested $1.1M in research and development during fiscal year 2025.

Nexalin Technology, Inc. (NXL) had 21M shares outstanding as of fiscal year 2025.

Nexalin Technology, Inc. (NXL) had a current ratio of 4.85 as of fiscal year 2025, which is generally considered healthy.

Nexalin Technology, Inc. (NXL) had a liabilities-to-equity ratio of 0.24 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Nexalin Technology, Inc. (NXL) had a return on assets of -177.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Nexalin Technology, Inc. (NXL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Nexalin Technology, Inc. (NXL) trades at 8.3x sales, its market capitalization divided by $217K revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Nexalin Technology, Inc. (NXL) held $3.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.0M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Nexalin Technology, Inc. (NXL) has an Altman Z-Score of -31.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Nexalin Technology, Inc. (NXL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nexalin Technology, Inc. (NXL) reported a net loss of $8.2M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nexalin Technology, Inc. (NXL) reported an operating loss of $8.4M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top